secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0000950170-23-018818
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte reports Q1 net loss $60.5M; VAX-24 Phase 2 meets endpoints in adults 65+
--------------------------------------------------------------------------------

- Net loss of $60.5M in Q1 2023 vs $39.0M in Q1 2022; R&D expenses $58.1M, up from $31.7M.
- Cash, cash equivalents and investments $949.9M as of March 31, 2023, excluding $545.1M net proceeds from recent public offering.
- Positive Phase 2 data for VAX-24 in adults 65+: at 2.2mcg dose, met OPA non-inferiority for 18/20 common serotypes vs PCV20 and superiority for all 4 unique serotypes.
- Dosed first participants in VAX-24 infant Phase 2 study; topline data expected by 2025.
- Completed $575M follow-on public offering in April 2023; VAX-31 IND submission expected H2 2023, Phase 1/2 data in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000095017023018818/0000950170-23-018818-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000095017023018818/pcvx-20230508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-018818

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer